We investigated the technique, early results and toxicity of curative stereotactic radiotherapy with the CyberKnife ® (Accuray Incorporated, Sunnyvale, California, USA) in 15 extracranial, extrapulmonary, extrahepatic, and extraspinal tumors. Fourteen tumors were located close to the bowel or esophagus. The PTV = GTV + 2-5 mm. The dose to the tumors varied from 10 fractions of 4 Gy up to 3 fractions of 20 Gy (median dose/fraction: 7 Gy; median number of fractions: 6), and depended on the proximity of the bowel. A small volume of the bowel was allowed to receive a dose of 6 Gy/fraction. The dose to the PTV was prescribed to the 75-85% isodose line. With a median follow up of 18 months, the 2-year local control and overall survival was 100%. Due to our flexible fractionation schedules, we were able to prescribe the dose to at least 90% of the PTV (median 95%) without increasing the dose to the bowel > 6 Gy/fraction. Five acute side effects were seen in four patients: two patients had transient grade 1 lymph edema in the leg, one patient complained of grade 1 pain in the abdomen and diarrhea, and one patient complained of grade 1 radiation dermatitis. Late toxicity such as grade 1 rectal bleeding, grade 1 diarrhea, grade 2 painful subcutaneous fibrosis, grade 2 pain in a surgical scar on the abdominal wall and an asymptomatic occlusion of the ureter was observed. Curative stereotactic radiotherapy treatment with the CyberKnife for extracranial, extrapulmonary, extrahepatic, and extraspinal, locally recurrent or solitary metastatic tumors is feasible and results in excellent local control and survival with low acute and late toxicity. A small volume of the bowel is able to tolerate a dose of 6 Gy per fraction for a maximum of 6 fractions.
Introduction
Extracranial stereotactic radiotherapy is often used as a treatment for primary or metastatic tumors in the lung, liver, or spine. The high dose and the precision with which it is delivered, results in an excellent local control with low toxicity. An actuarial 2-year local control of 85-95% for lung tumors and 82% for liver tumors has been described (1-4). Treatment of spinal metastases treated with stereotactic radiotherapy has reportedly resulted in an improvement or resolution of symptoms after treatment in 84-86% of cases (5, 6) . Outside these Technology in Cancer Research & Treatment, Volume 6, Number 6, December 2007 extracranial organs, the use of stereotactic radiotherapy has been limited due to proximity of radiation sensitive organs like the esophagus and the bowel. Also, the occurrence of inoperable solitary metastases outside lung or liver, or the appearance of small inoperable local recurrences without metastases are rare, which makes the use of stereotactic radiotherapy even more exceptional.
At the Erasmus MC-Daniel den Hoed Oncologic Center, extracranial stereotactic radiotherapy is performed with the CyberKnife ® (Accuray Incorporated, Sunnyvale, California, USA) (7, 8) . The image-guidance system of the CyberKnife not only corrects for patient motion during treatment (9, 10), but also for tumor motion with the use of the Synchrony ® (Accuray, Inc.) system (11) . With this 4-dimensional radiotherapy system, it is possible to deliver the dose precisely to the tumor and not to the radiation sensitive organs in the vicinity of the tumor, such as the bowel, the stomach, or the esophagus. The precise delivery of the radiation dose to the tumor, combined with the rapid dose fall-off outside the tumor -one of the physical advantages of stereotactic radiotherapy -results in a reduction of dose to the radiation sensitive organs and a high biological dose to the tumor. Since May 2005, we have treated 14 patients with 15 metastatic or inoperable recurrent local tumors in extracranial, extrapulmonary, extrahepatic, and extraspinal regions and we report our technique, early results, and toxicity.
Materials and Methods
Fifteen tumors in 14 patients were treated with curative intent: Three patients had a local recurrence and 11 patients had 12 metastases. One patient developed a second metastasis 4 months after the stereotactic treatment of the first metastasis and was, therefore, included twice because the first metastasis had a complete response on the stereotactic treatment. As screening, all the patients had a CT scan of the thorax, abdomen, and pelvis, and/or a PET scan before the treatment, and the patients were only included in the study if they had no other tumors. We made an exemption to this rule for one patient who had multiple metastases of a maligne haemangiopericytoma. Because the other metastases were not progressive the patient was included. Five of the metastases were located in para-aortic or pelvic lymph nodes, two were in the abdominal wall, two in muscle tissue, two in a rib, and one in the retroperitoneal fat. Two local recurrences were found in the pelvis and 1 in the neck. The primaries of these tumors are shown in Table I .
Three patients had received chemotherapy before the start of their stereotactic radiotherapy. Two of these had a partial response and one was progressive on chemotherapy. Three others had undergone surgery, one for an open biopsy, and the others for total resection of their tumors. However, during the resection, the margins were diagnosed as positive and subjected to intraoperative radiotherapy (10 Gy at 1 cm depth). For these two patients, stereotactic radiotherapy was the next treatment of first choice because in one, the target was close to his bowel and the other had previously received a dose of 70 Gy. To enable summation or comparison of the treatment plans, the doses were converted to EQD2 (equivalent dose delivered in 2-Gy fractions) using the linear quadratic model with an α/β late effects of 3 Gy and an α/β tumor of 10 Gy. Four other patients were previously irradiated with a median EQD2 of 48 Gy 3 (range, 36-76 Gy 3 ). The earlier treatments were a median of 13 months ago (range, 5-101 months).
The median age was 59 years (range, 38-74) and there were six males and eight females. In all the patients, markers were placed in or close to the tumor to allow a precise treatment with the CyberKnife. In total, 65 markers were placed, with a median of five markers per tumor. Because six of the tumors moved with respiration (e.g., rib or abdominal wall), they were treated using the Synchrony system of the CyberKnife.
The PTV equaled the GTV plus a 2-5-mm margin (median: 2 mm). The dose to the tumors varied from 10 fractions of 4 Gy up to 3 fractions of 20 Gy (median dose/ fraction: 7 Gy; median number of fractions: 6), and depended on the proximity of the bowel (Table I) . The maximum allowed dose in the bowel was 7 Gy/fraction. The dose to the PTV was prescribed to the 75-85% isodose line (median: 80%). The aim was to cover 95% of the PTV with the prescribed dose; however, if this resulted in a dose to the bowel of 7 Gy/fraction or more, then a lower coverage was allowed.
The median follow up was 18 months (range, 6-26 months).
Local failure was defined as tumor progression within the irradiation field. Locoregional progression was defined as tumor in the adjacent lymphnodes or tissue, but not in the irradiated field. Tumor progession at distance or new metastasis was defined as tumor progression outside the irradiation field or outside the adjacent lymphnodes or tissue. The local control and disease free survival was calculated according to the Kaplan Meier Method. Toxicity was scored according to the CTCAE score version 3.0 (12).
Results

Radiotherapy Planning
The median GTV and PTV were 35 and 61 cc (GTV range, 5-319 cc; PTV range, 10-398 cc), respectively. The median coverage of the GTV and PTV by the prescription dose was 99.6 and 94.9% (GTV range, 91.4-100%; PTV range, 82-98.7%), respectively. The median EQD2 was 63 Gy 10 , with a range of 48 to 150 Gy 10 . Only three patients received an EQD2 of 80 Gy 10 or more.
The volume of bowel irradiated with 6 Gy per fraction ranged in three patients between 0.04 and 1 cc, in eight patients between 1 and 13 cc, and was 61 cc in one patient. In the three remaining patients, the tumor was not in the vicinity of the bowel (one patient) or the dose per fraction was below 6 Gy (two patients). The volume of bowel irradiated with 36 Gy in 6 fractions was more than 10 cc in three patients, the volume of bowel irradiated with 30 Gy in 5 fractions was 8 cc in one patient and the volume of bowel irradiated with 18 Gy in 3 fractions was between 1 and 11 cc in five patients.
Local Control and Survival
The 24-month local control and overall survival (OS) was 100%. The 24-month disease free survival (DFS) was 27% ( Fig. 1) . Six patients had no evidence of disease. Five patients were diagnosed with new metastases, one patient treated for a metastasis in the abdominal wall had progression of tumor at the primary site (rectum), one patient had locoregional progression in a lymph node, and one patient was diagnosed with a new metastasis and a locoregional lymph node.
Side effects
Four patients experienced five acute side effects: two patients had transient grade 1 lymph edema in the leg after the irradiation of para-aortic lymph nodes (total dose: 36 and 45 Gy in 3 fractions); one patient complained of grade 1 abdominal pain, nausea, and diarrhea during and shortly after the treatment (total dose: 42 Gy in 6 fractions); and one patient complained of grade 1 radiation dermatitis (total dose: 30 Gy in 3 fractions).
Late toxicity was seen in six patients: Grade 1 rectal bleeding was seen in one patient with a locally recurrent rectal carcinoma. Twenty-eight cc of the rectum received an accumulated EQD2 of 100 Gy 3 . Two patients complained of chronically painful grade 2 subcutaneous fibrosis. The first patient received a total dose of 30 Gy in 3 fractions for a large metastasis in a rib from a CUP. One hundred fifty-one cc of subcutaneous tissue received a total dose of 27 Gy in 3 fractions (EQD2 = 65 Gy 3 ). The second patient had a local recurrence of a sarcoma in the neck. Forty-four cc of subcutaneous tissue received a total dose of 30 Gy in 10 fractions; however, the accumulated EQD2 for this volume was 134 Gy 3 due to reirradiation. One patient had grade 1 diarrhea. Sixty-one cc of small bowel received a total dose of 36 Gy in 6 fractions (EQD2 = 65 Gy 3 ). Grade 2 pain in a surgical scar on the belly was seen in one patient. Because we were not able to find the cause of the pain on MRI, we could not calculate a volume. The pain could be related to the stereotactic radiotherapy because the tumor of this patient received a total dose of 60 Gy in 3 fractions (EQD2 = 276 Gy 3 ). Asymptomatic occlusion of the ureter at the site of previous surgery and stereotactic radiotherapy was diagnosed in one patient with metastatic tumor in the lymphnodes who received 36 Gy in 3 fractions (EQD2 = 116 Gy 3 ).
Discussion
With a median follow-up of 18 months, the actuarial 2-year local control was 100%, although the median equivalent dose to the tumor in 2-Gy fractions (EQD2) was 63 Gy 10 . Only three patients received a dose higher than 80 Gy 10 EQD2. Despite these "low" equivalent total doses received by the majority of the patients, the local control was excellent. A longer follow-up period will be needed to confirm whether this dose was sufficient for local control.
Although the actuarial 2-year overall survival was 100%, the actuarial 2-year disease free survival was 27%. Solitary metastases do exist and the longest survivors of solitary metastases had tumors in the lung or liver (13). This is maybe the reason why the disease free survival is low. Because the disease free survival is low it is difficult to fully determine the benefit of the delivered therapy. On the other hand, the 2-year survival is still 100% and the most spectacular result was found in the patient with the metastatic pelvic lymphnodes from an ovarian cancer that was progressive on chemotherapy. After 26 months, she is still free of disease without side effects. However, eight patients already developed metastases or a locally recurrent tumor. Two patients failed in the neighborhood of the treated area, but also at a larger distance: one patient who was treated for a metastatic paraaortic lymph node did develop close to the radiation field another metastatic lymph node and a metastatic tumor in the base of skull. Both tumors were treated with stereotactic radiotherapy. The other patient who was treated for a locally recurrent tumor in the pelvis had tumor nodules in the vagina and a metastatic pelvic lymph node. She was then referred for treatment with chemotherapy.
We chose to use a variety of fractionation schemes because different kind of tumors were treated and were often located in proximity of small intestine or some other sensitive structure. For bowel, the dose constraint was set at 6 Gy/fraction and a small volume of bowel was allowed to receive 6
Gy/fraction. This proved to be a beneficial choice: The only patient who complained of acute and late belly pain and diarrhea was one whose irradiated bowel volume was 61 cc at the dose level of 6 Gy per fraction, with the fractionation schedule of 6 × 7 Gy. Koong et al. (14) treated inoperable pancreatic tumors with stereotactic radiotherapy with a single fraction of 25 Gy and reported that 50% of the duodenum was able to tolerate a dose of 14 Gy and 5% of the duodenum could even tolerate a dose of 22.5 Gy. At this dose level, two patients had grade 2 abdominal pain and two other patients complained of grade 1 nausea. However, the median follow up was five months with a median survival of eight months. Hoyer et al. (15) also treated inoperable pancreatic tumors with stereotactic radiotherapy to a total dose of 45 Gy in 3 fractions. They reported that the patients had an increase in pain and nausea at two weeks after treatment. Three months after treatment, 94% of the patients had grade ≥2 pain and four patients experienced severe mucositis or ulceration observed by endoscopy. Beitler et al. (16) treated nine primary renal cell tumors with 5 fractions of 8 Gy and reported that two patients complained of nausea and vomiting during treatment. However, the dose to the bowel was not reported. Madsen et al. (17) treated early stage prostate cancer with stereotactic radiotherapy to a total dose of 33.5 Gy in 5 fractions (6.7 Gy/fraction). Acute and late grade 2 gastrointestinal toxicity was observed in 13% and 7.5% of the patients, respectively. A mean rectal volume of 3.66 cc received 90% of the prescribed dose (= 6.03 Gy/fraction). Although these articles use different treatment schedules, it can be speculated that the small bowel volumes are able to tolerate high doses per fraction and when considering an EQD2, a dose of 60 Gy 3 or more can be tolerated.
Acute side effects as transient lymph edema was diagnosed in two patients and grade 1 radiation dermatitis in one patient. The lymph edema started one to two weeks after the last irradiation of para-aortic nodes to a dose of 35 and 45 Gy in 3 fractions and disappeared one to two months later. The grade 1 dermatitis was seen after the treatment of a large metastasis in a rib from a CUP treated to a total dose of 30 Gy in 3 fractions.
Late toxicity was seen in six patients. In four of the six patients, the organ at risk received an EQD2 of 100 Gy 3 or more:
The first patient with a locally recurrent rectal carcinoma had grade 1 rectal bleeding. Five months after the first radiotherapy treatment the patient was retreated with stereotactic radiotherapy and 28 cc of bowel received an accumulated EQD2 dose of 100 Gy 3 . The second patient was diagnosed with a local recurrence 20 months after the postoperative radiotherapy treatment of the primary tumor (70 Gy in 35 fractions) and was treated with resection, intraoperative radiotherapy (10 Gy) and postoperative stereotactic radiotherapy (40 Gy in 10 fractions) due to positive margins. The pain disappeared after six months and also the fibrosis reduced.
Forty-four cc of subcutaneous tissue received a total dose of 30 Gy in 10 fractions; however, the accumulated EQD2 for this volume was 134 Gy 3 due to reirradiation. The third patient complained of a grade 2 irradiating pain in and around an abdominal scar from a previous operation five months after the stereotactic treatment of 60 Gy in 3 fractions (EQD2 = 276 Gy 3 ). It is not clear at this point whether the pain is due to the earlier surgery or the radiotherapy, because the patient was not able to tell from where the pain was arising, a MRI scan was not able to find a cause of the pain, and the distance from the scar to the stereotactic treatment site was more than 20 cm. One explanation could be that the patient has a referring pain from the irradiated retroperitoneal fat to the skin. The fourth patient had a asymptomatic occlusion of the ureter at the site of previous surgery (one lymph node dissection and one biopsy) and stereotactic treatment (3 × 12 Gy, EQD2=116 Gy 3 ). This patient had a local recurrence in the iliac lymph nodes where previously a lymph node dissection was performed. The surgeon had planned a lymph node dissection as treatment for the local recurrence, however, due to the fibrosis he only performed an open biopsy. The cause of this complication is probably the extensive surgery combined with high dose radiotherapy.
The late toxicity in the organs at risk of two remaining patients was below 100 Gy 3 EQD2. The first patient had a PTV volume of 336 cc close to skin and was irradiated with a total dose of 30 Gy in 3 fractions. One hundred fifty-one cc of subcutaneous tissue received a total dose of 27 Gy in 3 fractions (EQD2 = 65 Gy 3 ). The other patient complained of grade 1 pain in the abdomen after the stereotactic treatment to a metastatic lymphnode (6 × 7 Gy). Sixty-one cc of small bowel received a total dose of 36 Gy in 6 fractions (EQD2 = 65 Gy 3 ).
Ninety percent of the PTV received the prescribed dose or more in all the patients but one, who had a tumor in the abdominal wall. The patient's bowel was fixed to the abdominal wall due to surgery and the distance between the tumor and the bowel was only a few millimeters. In this case, we decided to allow a maximum dose of 6 Gy per fraction to the bowel and to underdose the PTV with a dose 18% lower than the prescribed dose (5 × 8 Gy). Until now, 13 months after the treatment, the metastasis is still under local control but a local recurrence of the rectal tumor has been diagnosed and the patient has been treated with radiotherapy because the patient was found to be inoperable.
Three patients received before the start of the radiotherapy chemotherapy. The patient who was progressive on the chemotherapy has until now no evidence of disease. However, the two other patients developed new metastasis. In total, six of the 14 patients did not develop until now metastasis. For this reason, it is not clear if we should give then all chemotherapy before or after the radiotherapy.
Conclusion
The first experience with curative stereotactic radiotherapy treatment with the CyberKnife for extracranial, extrapulmonary, extrahepatic, and extraspinal, locally recurrent or solitary metastatic tumors shows that this treatment approach is feasible and resulted in excellent 2-year local control and overall survival of 100% with low acute and late toxicity. A small volume of bowel is able to tolerate a dose of 6 Gy per fraction for a maximum of 6 fractions.
